US Patent

US12318375 — Method of treatment with tradipitant

Method of Use · Assigned to Vanda Pharmaceuticals Inc · Expires 2036-08-09 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of treatment using the NK-1 antagonist tradipitant.

USPTO Abstract

This application relates to a method of treatment with the NK-1 antagonist, tradipitant.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4396`	—

Patent Metadata

Patent number: US12318375
Jurisdiction: US
Classification: Method of Use
Expires: 2036-08-09
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.